TUHURA BIOSCIENCES INC

NASDAQ: HURA (TuHURA Biosciences, Inc.)

Kemas kini terakhir: 24 Jan, 4:13AM

4.62

-0.15 (-3.14%)

Penutupan Terdahulu 4.77
Buka 4.68
Jumlah Dagangan 121,720
Purata Dagangan (3B) 317,667
Modal Pasaran 195,354,384
Harga / Buku (P/B) 12.05
Julat 52 Minggu
2.84 (-38%) — 14.60 (215%)
Tarikh Pendapatan 12 Feb 2025 - 17 Feb 2025
EPS Cair (TTM) -0.960
Jumlah Hutang/Ekuiti (D/E MRQ) 1.67%
Nisbah Semasa (MRQ) 3.00
Aliran Tunai Operasi (OCF TTM) -15.63 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -15.19 M
Pulangan Atas Aset (ROA TTM) -90.68%
Pulangan Atas Ekuiti (ROE TTM) -332.67%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok TuHURA Biosciences, Inc. Menurun -

AISkor Stockmoo

-1.0
Konsensus Penganalisis -0.5
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal -4.0
Purata -1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
HURA 195 M - - 12.05
LEGN 7 B - - 7.75
IMCR 2 B - - 4.69
JBIO 309 M - - -
OKUR 31 M - - 0.370
QTTB 27 M - - 3.55

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 41.96%
% Dimiliki oleh Institusi 8.43%
13.2013.2012.6012.6012.0012.0011.4011.4010.8010.80Harga Sasaran MedianQ4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
2.84 (-38%) — 14.60 (215%)
Median 12.00 (159.74%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 16 May 2025 12.00 (159.74%) Beli 3.92

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
01 Jul 2025 Pengumuman TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
30 Jun 2025 Pengumuman TuHURA Biosciences Completes Acquisition of Kineta
24 Jun 2025 Pengumuman TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
23 Jun 2025 Pengumuman TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
09 Jun 2025 Pengumuman FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
03 Jun 2025 Pengumuman TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
02 Jun 2025 Pengumuman TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
15 May 2025 Pengumuman TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
13 May 2025 Pengumuman TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
05 May 2025 Pengumuman TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
28 Apr 2025 Pengumuman TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual ...
Papar semua
2.842.842.572.572.302.302.032.031.771.77Jun 26Jun 26Jun 27Jun 27Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3Jul 7Jul 7Jul 8Jul 8

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.1000.100-0.000-0.000-0.100-0.100-0.200-0.200-0.300-0.300MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda